Harrow (NASDAQ:HROW) Earns “Buy” Rating from HC Wainwright

Harrow (NASDAQ:HROW)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They currently have a $57.00 price target on the stock. HC Wainwright’s target price indicates a potential upside of 108.94% from the company’s previous close.

Separately, B. Riley dropped their target price on Harrow from $73.00 to $69.00 and set a “buy” rating for the company in a report on Wednesday, December 4th.

Harrow Stock Up 1.1 %

Shares of HROW opened at $27.28 on Tuesday. The company has a debt-to-equity ratio of 3.23, a quick ratio of 1.44 and a current ratio of 1.55. The stock has a 50 day moving average price of $29.83 and a 200 day moving average price of $38.56. The stock has a market capitalization of $971.58 million, a price-to-earnings ratio of -29.02 and a beta of 0.69. Harrow has a one year low of $9.30 and a one year high of $59.23.

Hedge Funds Weigh In On Harrow

Several hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in shares of Harrow by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 1,872,100 shares of the company’s stock valued at $62,809,000 after acquiring an additional 5,225 shares during the last quarter. Braidwell LP raised its holdings in Harrow by 106.3% during the fourth quarter. Braidwell LP now owns 907,039 shares of the company’s stock worth $30,431,000 after purchasing an additional 467,401 shares during the last quarter. State Street Corp raised its holdings in Harrow by 2.2% during the third quarter. State Street Corp now owns 730,973 shares of the company’s stock worth $32,865,000 after purchasing an additional 15,554 shares during the last quarter. Geode Capital Management LLC increased its position in Harrow by 0.6% during the third quarter. Geode Capital Management LLC now owns 722,730 shares of the company’s stock worth $32,500,000 after buying an additional 3,960 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. increased its position in Harrow by 6.7% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 664,714 shares of the company’s stock worth $22,301,000 after buying an additional 41,896 shares in the last quarter. Institutional investors and hedge funds own 72.76% of the company’s stock.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.